## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Lal et al

U.S. Serial No. : 10/611,539

Filing Date : July 1, 2003

For : INHIBITORS OF CYCLIN DEPENDENT

KINASES AND THEIR USE

Group Art Unit : 1626

745 Fifth Avenue New York, NY 10151

## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Enclosed are copies of publications for the Examiner's review and

## consideration:

 Schwartz et al, "Phase I Study of Cyclin-Dependent Kinase Inhibitor Flavopiridol in Combination with Paclitaxel in Patients with Advanced Solid Tumors", Journal of Clinical Oncology, Vol. 20, No. 8, April 15, 2002, pp. 2157-2170;

- Tan et al, "Phase I Clinical and Pharmacokinetic Study of Flavopiridol Administered
  as a Daily I-Hour Infusion in Patients with Advanced Neoplasms", Journal of clinical
  Oncology, Vol. 20, No. 19, October 1, 2002, pp. 4074-4082;
- Hirama et al, BLOOD, "Role of the Cyclin-Dependent Kinase Inhibitors in the Development of Cancer", The Journal of The American Society of Hematology, August 1, 1995, Blood, Vol. 88, No. 3, August 1, 1995, pp. 841-854;
- Edward A. Sausville, "Cyclin-Dependent Kinases: Novel Targets for Cancer Treatment", Developmental Therapeutics Program, pp. 9-21;
- Elsayed et al, "Selected Novel Anticancer Treatments Targeting Cell Signaling Proteins", The Oncologist: 2001; 6: pp. 517-537;
- Meier et al, "Properties and Potential Applications of Chemical Inhibitors of Cyclin-Dependent Kinases". Pharmacol. Ther., Vol 82, Nos., 2-3, pp. 279-284, 1999.
- Sausville et al, "Cyclin-Dependent Kinases: Initial Approaches to Exploit a Novel Therapeutic Target", Pharmacol, Ther. Vol. 82, Nos. 2-3, pp. 285-292, 1999;
- Parker et al, "Early Induction of Apoptosis in Hematopoieti Cells Lines After Exposure to Flavopiridol", The American Society of Hematology", Blood, Vol. 91, No. 2, January 15, 1998; pp. 458-465.

We have enclosed a copy of PTO-1449 which is considered part of the Information Disclosure Statement. If a fee is required, the Examiner is hereby authorized to charse our Deposit Account 50-0320.

2

PATENT 516745-2001.1

Applicant respectfully requests that the Examiner consider and make of record the documents cited herein and that a copy of Form PTO-1449 be initialed by the Examiner and returned to the undersigned.

Respectfully submitted,

FROMMER LAWRENCE & HAUG LLP Attorneys for Applicants

By Howard C. Lee

Reg. No. 48,104

Tel. (212) 588-0800

Bred on From 770-1449 (2009) LIST OF REPERENCIS CITED BY APPLICANT (On overal about if necessary)					ATTY. DOCKET NO. SERIAL NO. 516745-2001.1 10/611,539				
				APPLICANT	APPLICANT				
				Lal et al					
				FILING DATE	FILING DATE GROUP				
				July 1, 2003		1626			
			U.	S. PATENT DOCUMENTS					
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS		DATE OPRIATE	
	AA								
			FOR	EIGN PATENT DOCUMENTS					
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION		
			l i				YES	NO	
	AB								
		01	THER PRIOR ART (I	Klading Author, Title, Date, Pertinent F	agos, Etc.)				
	AC	Schwartz et in Patients v pp. 2157-21	with Advanced Se	y of Cyclin-Dependent Kinese olid Tumors", Journal of Clinic	Inhibitor Flavo II Oncolegy, V	piridol in Combin ol. 20, No. 8, Ap	nation with ril 15, 2002	Paclita:	
	AD		with Advanced N	nd Pharmacokinetic Study of F coplasms", Journal of clinical					
	AD AE	in Patients v pp. 4074-40	with Advanced N 182; I, BLOOD, "Role The American Soc		Oncology, Vol.	20, No. 19, Octob the Development	ber 1, 2002	. The	
		in Patients v pp. 4074-40  Hirama et al  Journal of T pp. 841-854  Edward A. S	with Advanced N 182; I, BLOOD, "Role The American Soc I;	coplasms", Journal of clinical of the Cyclin-Dependent Kin- iety of Hematology, August 1, -Dependent Kinases: Novel Ti	Oncology, Vol.: ase Inhibitors in 1995, Blood, V	the Development ol. 88, No. 3, Au	t of Cancer agust 1, 199	", The	
	AE	in Patients v pp. 4074-40 Hirama et al Journal of T pp. 841-854 Edward A. S Therapeutic	with Advanced N 182; I, BLOOD, "Role The American Soc i; Sausville, "Cyclin a Program, pp. 9- I, "Selected Nove	coplasms", Journal of clinical of the Cyclin-Dependent Kin- iety of Hematology, August 1, -Dependent Kinases: Novel Ti	Oncology, Vol. : ase Inhibitors in 1995, Blood, V argets for Cance	20, No. 19, Octob the Development of 88, No. 3, Au r Treatment", De	t of Cancer gust 1, 199	", The 15,	
	AE AF	in Patients - pp. 4074-46  Hiramae de l'autre de l'autr	with Advanced N 182; 1, BLOOD, "Role file American Socie; Sausville, "Cyclin a Program, pp. 9- 1, "Selected Nove 37; "Properties and F	coplasma", Journal of clinical of the Cyclin-Dependent Kin- iety of Hematology, August 1,Dependent Kinases: Novel Ti 21;	Oncology, Vol. :  sse Inhibitors in 1995, Blood, V  sargets for Cance  tring Cell Signal	20, No. 19, October the Development of 88, No. 3, Au r Treatment", De ing Proteins", Th	t of Cancer agust 1, 199 welopmenta	", The 15,	
	AF AG	in Patients v pp. 4074-46  Hirzma et al Journal of 1 pp. 841-854  Edward A. 3 Therapeutic  Elsayed et a 6: pp. 517-5  Meier et al, Pharmacol, Sausville et	with Advanced N 182;  1, BLOOD, "Role The American Soc ;  Sansville, "Cyclin a Program, pp. 9- 4, "Selected Nove 37; "Properties and F Ther., Vol 82, Ne al, "Cyclin-Depe	ooplasma", Journal of clinical of the Cyclin-Dependent Kin- iety of Hematology, August 1, Dependent Kinaser: Novel T 21; Id Anticancer Treatments Target Octential Applications of Chem	oncology, Vol. :  see Inhibitors in 1995, Blood, V  sergets for Cance  ting Cell Signal  ical Inhibitors o	the Development of 88, No. 3, Au r Treatment", De ing Proteins", Th	t of Cuncer t of Cuncer t gust 1, 195 evelopments is Oncologi	", The 5,	
	AF AG AH	in Patients v pp. 407-44  Hirrams et al  Journal of 1 pp. 841-354  Edward A. 3  Therapeuic  Elisayed et a  Gr. pp. 517-5  Meier et al,  Pharmool,  Sausville et  Pharmool,  Parker et al,	with Advanced N 182;  BLOOD, "Role The American Soc ;  Sausville, "Cyclin a Program, pp. 9- a Propram, pp. 9- 37;  "Properties and F Ther., Vol 82, Ne al, "Cyclin-Depe Ther. Vol. 82, Ne Flavopiridol", Tl	ooplasme", Journal of clinical of the Cyclin-Dependent Kinnical of the Cyclin-Dependent Kinnical of the Cyclin-Dependent Kinnical Open State of Hematology, August 1, -Dependent Kinnical Kinnical State of Line 21; 81 Anticancer Treatments Target Contestal Applications of Chem. 2, -23, pp. 279-284, 1999; ondert Kinnical Kinnical Approach of Chem.	Oncology, Vol. :  see Inhibitors in 1995, Blood, V surgets for Cance ting Cell Signal ical Inhibitors o has to Exploit a Cells Lines Aft	20, No. 19, Octol the Development ol. 88, No. 3, Au r Treatment", De ing Proteins", Th f Cyclin- Depend Novel Therapeut	t of Cancer t of Cancer tegast 1, 195 evelopments the Oncologia dent Kinase	The is,	
XAMINER	AF AG AH AI	in Pationa v pp. 4074-6 Hirrame et al Journal of T pp. 841-545 Edward A. 5 Therapounic Einsye of S America et al, Pharmocol, Saurville et Pharmocol, Parker et al, Exposure to	with Advanced N 182;  BLOOD, "Role The American Soc ;  Sausville, "Cyclin a Program, pp. 9- a Propram, pp. 9- 37;  "Properties and F Ther., Vol 82, Ne al, "Cyclin-Depe Ther. Vol. 82, Ne Flavopiridol", Tl	ooplasma", Journal of clinical of the Cyclin-Depundent Kinnical of the Cyclin-Depundent Kinnical of the Cyclin-Depundent Kinnica Novel Ti 21.  8 Anticancer Treatments Target of tential Applications of Chem. p. 23, pp. 279-284, 1999, others. Kinnical Applications of Chem. p. 23, pp. 279-284, 1999, others. Kinnical Applications of Chem. p. 23, pp. 285-292, 1999, others. Kinnical Applications of Chem. p. 23, pp. 285-292, 1999, others. Kinnical Applications of Chem. p. 23, pp. 285-292, 1999, of Application in Hernatopoleic for Application in Hernatopoleic for Proposition in Hernatopoleic for	Oncology, Vol. :  see Inhibitors in 1995, Blood, V surgets for Cance ting Cell Signal ical Inhibitors o has to Exploit a Cells Lines Aft	20, No. 19, Octol the Development ol. 88, No. 3, Au r Treatment", De ing Proteins", Th f Cyclin- Depend Novel Therapeut	t of Cancer t of Cancer tegast 1, 195 evelopments the Oncologia dent Kinase	The is,	
XAMINER	AF AG AH AI	in Pationa v pp. 4074-6 Hirrame et al Journal of T pp. 841-545 Edward A. 5 Therapounic Einsye of S America et al, Pharmocol, Saurville et Pharmocol, Parker et al, Exposure to	with Advanced N 182;  BLOOD, "Role The American Soc ;  Sausville, "Cyclin a Program, pp. 9- a Propram, pp. 9- 37;  "Properties and F Ther., Vol 82, Ne al, "Cyclin-Depe Ther. Vol. 82, Ne Flavopiridol", Tl	sophum", Journal of clinical of the Cyclus Dynamical Kini of the Cyclus Dynamical in Grant Commission  - Dependent Kinners Never 1  11  12  13  14  15  16  16  16  16  16  16  16  16  16	Oncology, Vol. :  see Inhibitors in 1995, Blood, V surgets for Cance ting Cell Signal ical Inhibitors o has to Exploit a Cells Lines Aft	20, No. 19, Octol the Development ol. 88, No. 3, Au r Treatment", De ing Proteins", Th f Cyclin- Depend Novel Therapeut	t of Cancer t of Cancer tegast 1, 195 evelopments the Oncologia dent Kinase	The is,	